1 Ebinger M, Winter B, Wendt M, et al. Effect of the

use of ambulance-based thrombolysis on time to

thrombolysis in acute ischemic stroke:a randomized

clinical trial[J]. JAMA, 2014, 311:1622-1631.

2 Ebinger M, Kunz A, Wendt M, et al. Effects of golden

hour thrombolysis:A Prehospital Acute Neurological

Treatment and Optimization of Medical Care in

Stroke (PHANTOM-S) Substudy[J]. JAMA Neurol,

2014, doi:10.1001/jamaneurol.2014.3188[Epub ahead

of print].

3 Rajan S, Baraniuk S, Parker S, et al. Implementing a

mobile stroke unit program in the United States:Why,

how, and how much?[J ]. JAMA Neurol, 2014,

doi:10.1001/jamaneurol.2014.3618[Epub ahead of print].

4 Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle

times for tissue plasminogen activator administration

and clinical outcomes in acute ischemic stroke before

and after a quality improvement initiative[J]. JAMA,

2014, 311:1632-1640.

5 Huisa BN, Stemer AB, Walker MG, et al. Transcranial

laser therapy for acute ischemic stroke:a pooled

analysis of NEST-1 and NEST-2[J]. Int J Stroke, 2013,

8:315-320.

6 Ha c k e W, S c h e l l i n g e r PD, Al b e r s GW, e t

al. Transcranial laser therapy in acute st roke

treatment:results of Neurothera effectiveness and

safety trial 3, a phase III clinical end point device

trial[J]. Stroke, 2014, 45:3187-3193.

7 Chamorro A, Amaro S, Castellanos M, et al. Safety

and efficacy of uric acid in patients with acute stroke

(URICO-ICTUS):a randomised, double-blind phase

2b/3 trial[J]. Lancet Neurol, 2014, 13:453-460.

8 He J, Zhang Y, Xu T, et al. CATIS Investigators.

Effects of immediate blood pressure reduction on

death and major disability in patients with acute

ischemic stroke:the CATIS randomized clinical

trial[J]. JAMA, 2014, 311:479-489.

9 The ENOS Trial Investigators. Efficacy of nitric oxide,

with or without continuing antihypertensive treatment,

for management of high blood pressure in acute stroke

(ENOS):a partial-factorial randomised controlled

trial[J]. Lancet, 2014, doi:S0140-6736(14)61121-

1[Epub ahead of print].

10 J ü t t l e r E , Un t e r b e r g A, Wo i t z i k J , e t a l .

Hemicraniectomy in older patients with extensive

middle-cerebral-artery stroke[J]. N Engl J Med, 2014,

370:1091-1100.

11 Flint AC, Conell C, Rao VA, et al. Effect of statin use

during hospitalization for intracerebral hemorrhage

on mortality and discharge disposition[J]. JAMA

Neurol, 2014, 71:1364-1371.

12 Wang Y, Zhao X, Liu L, et al. Prevalence and

outcomes of symptomatic intracranial large artery

stenoses and occlusions in China:The Chinese

Intracranial Atherosclerosis (CICAS) Study[J]. Stroke,

2014, 45:663-669.

13 Bos D, Por t egie s ML, van de r Lug t A, et al.

Intracranial carotid artery Atherosclerosis and the risk

of stroke in Whites:The Rotterdam Study[J]. JAMA

Neurol, 2014, 71:405-411.

14 Gladstone DJ, Spring M, Dorian P, et al. Atrial

fibrillation in patients with cryptogenic stroke[J]. N

Engl J Med, 2014, 370:2467-2477.

15 Sanna T, Diener HC, Passman RS, et al. Cryptogenic

stroke and underlyingatrial fibrillation[J]. N Engl J

Med, 2014, 370:2478-2486.

16 Hart RG, Diener HC, Coutts SB, et al. Embolic strokes

of undetermined source:the case for a new clinical

construct[J]. Lancet Neurol, 2014, 13:429-438.

17 Janssen LP. Rivaroxaban versus Aspirin in Secondary

Prevention of Stroke and Prevention of Systemic

Embolism in Patients with Recent Embolic Stroke

of Undetermined Source[EB/OL]. https://www.

clinicaltrials.gov/ct2/show/NCT02313909?term=NAV

IGATE+ESUS&rank=1[2014-02-08],(2015-01-10).

18 Boehringer Ingelheim. Dabigatran Etexilate for

Secondary St roke Prevention in Patients With

Embolic Stroke of Undetermined Source (RE-SPECT

ESUS)[EB/OL]. https://www.clinicaltrials.gov/ct2/

show/NCT02239120?term=RE-SPECT+ESUS &

rank=110],(2015-01-10).